Cytomos has secured £4m to scale up market testing of its technology platform.
The investment round was led by existing investors Archangels, with participation from Old College Capital, Scottish Enterprise and new investor British Business Bank.
The Edinburgh-based life science company has developed Cytomos Dielectric Spectroscopy (CDS) to address the unmet needs of the biopharmaceutical industry, providing a high-speed, scalable and low-cost platform beyond current cell analysis systems.
The new funding should enable Cytomos to advance the development of its technology and substantially expand the team. The company is targeting commercialisation of its platforms in 2024.
Read more HERE.
